만성 신장 질환 : 세계 시장 및 기술

The global market for chronic kidney disease was valued at $52.9 billion in 2025 and is estimated to reach $82.6 billion by 2030, at a compound annual growth rate (CAGR) of 9.3% from 2025 through 2030.

The North American market for chronic kidney disease was valued at $24.6 billion in 2025 and is estimated to reach $37.5 billion by 2030, at a CAGR of 8.8% from 2025 through 2030.

The Asia-Pacific market for chronic kidney disease was valued at $9.1 billion in 2025 and is estimated to reach $15.4 billion by 2030, at a CAGR of 11.1% from 2025 through 2030.

Report Scope

The global market for chronic kidney disease is segmented by technology type, pharmaceutical drugs, and end users. From a technological perspective, the market is divided into diagnostic, therapeutic, and renal replacement solutions. Diagnostic technologies encompass biomarker-driven assays, imaging techniques, point-of-care testing, and genomic and proteomic screening, which facilitate early diagnosis and ongoing disease assessment. Therapeutic technologies encompass conventional drug treatments, innovative cell- and gene-based therapies, and advanced drug delivery systems, designed to slow disease progression and enhance patient outcomes. Renal replacement technologies, such as hemodialysis, peritoneal dialysis, and bioengineered artificial kidneys, are predominantly utilized in late-stage and end-stage CKD management.

In terms of pharmaceutical drugs, the market is segmented by CKD stage (Stage 1-5) and by medications used for dialysis and post-transplant care. This segmentation reflects the varying therapeutic requirements associated with disease severity and treatment settings. Based on end users, the market is classified into hospitals, clinics, and home-based or in-house dialysis settings. Hospitals and clinics account for the largest share due to comprehensive care capabilities, but the home care segment is experiencing rapid growth driven by increased patient preference, convenience, and advances in dialysis technologies. For market estimates, data has been provided for 2024 as the base year, 2025 as the estimated year, and with forecasts for 2026 through 2030.

Report Includes

• 57 data tables and 43 additional tables
• In-depth analysis of the global markets for chronic kidney diseases (CKD) and related technologies
• Analyses of the global market trends, with historic revenue data from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
• Estimates of the current market size and revenue forecasts, along with a corresponding market share analysis by product type, application, end-user and region
• Facts and figures pertaining to the market dynamics, technological advances, regulations, prospects, reimbursement practices, and the impact of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Information on current state of chronic kidney disease, with an emphasis on biomarkers, diagnostic methods and mobile apps that support effective disease state management
• Key insight into research on CKD comorbidities such as diabetes and metabolic disease, as well as treatment methods and diagnostics
• Review of key granted and published patents
• Analysis of the industry structure, including companies' shares and global rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Company profiles of major players within the industry, including Fresenius Medical Care AG, Baxter, B. Braun SE, NIPRO, and Medtronic

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Growth in Healthcare Spending and Focus on Chronic Conditions
• Aging Populations and Shifting Demographic Patterns
• Economic Development, Urbanization, and Lifestyle-Related Health Risks
• Investment in Healthcare Infrastructure and Broader Access to Care
• Impact of U.S. Tariffs and Global Trade Dynamics
• Porter's Five Forces Analysis
• Potential for New Entrants to the Market
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of Substitutes
• Competition in the Industry

Chapter 3 Market Dynamics

• Overview
• Market Drivers
• Growing Prevalence of Chronic Diseases Such as Diabetes and Hypertension Globally
• Progression Rate from Early-Stage CKD to End-Stage Renal Disease (ESRD)
• Increased Number of Dialysis Centers and Laboratories
• Market Restraints
• High Capital and High Cost of Treatment and Limited Reimbursement
• Stringent Regulatory and Approval Requirements
• Low Awareness and Late Diagnosis
• Market Opportunities
• Growing Investment in Regenerative Medicine and Biologic Therapies
• Expanding Research and Development Efforts by Industry Leaders
• Research and Development Initiatives from Key Companies

Chapter 4 Regulatory Landscape

• Overview
• Regulatory Scenario in the U.S.
• Regulatory Scenario in Europe
• Regulatory Scenario in Asia-Pacific
• Japan
• China
• India
• Regulatory Scenario in the Rest of the World

Chapter 5 Emerging Technologies and Patent Analysis

• Overview
• Emerging Trends/Technologies
• Advanced Diagnostic Technologies
• Novel Therapeutics and Biologics
• Wearable and Implantable Renal Devices
• Artificial Intelligence, Machine Learning, and Digital Health
• Regenerative Medicine and Tissue Engineering
• Patent Analysis

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by Technology
• Takeaways
• Diagnostic Technologies
• Therapeutic Technologies
• Renal Replacement Technologies
• Market Breakdown by Pharmaceutical Drugs
• Takeaways
• Market Breakdown by End User
• Takeaways
• Geographic Breakdown
• Market Breakdown by Region
• Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Competitive Analysis
• Strategic Analysis
• Investment Landscape

Chapter 8 Sustainability in the Chronic Kidney Disease Market: ESG Perspective

• Overview
• Sustainability Trends and Initiatives of AI in the Chronic Kidney Disease Industry
• ESG Risk Ratings
• Concluding Remarks from BCC Research

Chapter 9 Appendix

• Research Methodology
• Abbreviations
• References
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTELLAS PHARMA INC.
• BAXTER
• BAYER AG
• B. BRAUN SE
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• FRESENIUS MEDICAL CARE AG
• JOHNSON & JOHNSON
• LILLY USA LLC
• NOVARTIS AG
• PFIZER INC.
• SIEMENS HEALTHINEERS AG
• THERMO FISHER SCIENTIFIC INC.
• TORAY INDUSTRIES INC.
• Emerging Startups/Market Disruptors